small sample size could explain the lack of statistical significance. Table 1 shows a crosstabulation of all adverse events, regardless of whether or not they were supplement-related, summarized by MedDRA Preferred Term (Medical Dictionary for Regulatory Activities; currently implemented by the FDA within its Adverse Event Reporting System (AERS)), and compared between the Xenadrine RFA-1 and Placebo groups.
Analysis of adverse event relation to Xenadrine RFA-1t Table 2 shows a crosstabulation of supplement-related adverse events, summarized by MedDRA Preferred Term, and compared between the Xenadrine RFA-1 and placebo groups. AE determined to be possibly, probably or definitely related to the subject were included in this analysis. One subject in the treatment group dropped out due to symptoms of mild chest pain and shortness of breath. There were no serious adverse events. We observed no differences between placebo and treatment with regard to cardiovascular measurements (echocardiograms, electrocardiograms and blood pressure). Our conclusions regarding the safety of the treatment in this small group of healthy subjects treated for 2 weeks remains unchanged. 
DS Kalman et al

